Vaccine Testing for SARS-CoV-2
ELISA and Viral Neutralization Assays
With numerous candidate vaccines for SARS-CoV-2 soon to be tested, the key to rapid product licensure will be scale of testing, quality of methods available, and demonstrated experience by the immunogenicity testing laboratory.
Get all the details in this insight brief published by Bob Bailer, Ph.D., Sr. Director, Vaccines.
Complete the form below to access this insight brief